---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033079"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:23:13.760305+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics

## Summary
- Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
- Exact Sciences last trading day was March 20, 2026; shares converted to $105 cash.
- Deal adds Cologuard, Oncotype DX, Oncodetect, Cancerguard cancer screening diagnostics.
- Abbott becomes leader in $60B U.S. cancer screening and precision oncology diagnostics market.
- Acquisition adds growth vertical to Abbott's high-single-digit growth expectations.

## SEC filing metadata
- accession: 0001104659-26-033079
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/0001104659-26-033079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/tm268709d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033079
- JSON: https://secwatch.observer/filing/0001104659-26-033079.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.